Agenus surcharges on $340M cancer trial funding
Agenus doubled in a single session after securing $340 million in funding for a colon cancer trial, though speakers questioned whether short-dated call buyers paid too high a volatility premium.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.